8-K: Cardiff Oncology Announces Positive Initial Data for Onvansertib in First-Line RAS-Mutated mCRC Trial

Cardiff Oncology's Phase 2 trial of onvansertib in combination with standard-of-care for first-line RAS-mutated metastatic colorectal cancer shows a 64% objective response rate in the 30mg dose arm.

Summary

• Cardiff Oncology announced positive initial data from its Phase 2 CRDF-004 trial evaluating onvansertib in combination with standard-of-care (SoC) for first-line RAS-mutated metastatic colorectal cancer (mCRC).
• The trial is a randomized study with three arms: 20mg onvansertib plus SoC, 30mg onvansertib plus SoC, and SoC alone.
• The primary endpoint is objective response rate (ORR), and secondary endpoints include progression-free survival (PFS), duration of response (DOR), and safety.
• Initial data from 30 evaluable patients showed a 64% ORR in the 30mg onvansertib arm, compared to a 50% ORR in the 20mg onvansertib arm and a 33% ORR in the control arm.
• The 30mg dose of onvansertib also demonstrated deeper tumor regression compared to the 20mg dose and the control arm.
• Onvansertib was well-tolerated at both doses with no major or unexpected toxicities observed.
• The company expects to provide additional clinical data from the CRDF-004 trial in the first half of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive initial results from a Phase 2 trial, showing a significant improvement in objective response rate with onvansertib. The safety profile is also reported as favorable. The sentiment is very positive, but tempered by the fact that it is still early data from an ongoing trial.

Positives

• The 64% ORR in the 30mg onvansertib arm is significantly higher than the 33% ORR in the control arm.
• The higher dose of onvansertib (30mg) showed a better response rate and deeper tumor regression than the lower dose (20mg).
• Onvansertib was well-tolerated with no major or unexpected toxicities.
• The data suggests onvansertib can be safely combined with both FOLFIRI and FOLFOX chemotherapy backbones.
• The trial is designed to potentially support accelerated and full approval of onvansertib.

Negatives

• The data is from an interim analysis of an ongoing trial and may change as the trial progresses.
• Some patients experienced adverse events, although they were generally manageable.
• The control arm still had a 33% response rate, indicating that standard of care is still effective for some patients.

Risks

• Clinical trials are lengthy and expensive with uncertain outcomes.
• Trial results may not be predictive of future trial results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or safety risks.
• The company may need additional financing.
• There are risks related to business interruptions, including pandemics and cyber-attacks.
• There are uncertainties of government or third-party payer reimbursement.
• The company depends on key personnel.
• There is substantial competition in the market.
• There are uncertainties of patent protection and litigation.
• The company depends on third parties.
• There are risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

Cardiff Oncology expects to provide additional clinical data from the CRDF-004 trial in the first half of 2025.

Management Comments

• Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology, stated that they are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care.
• Mark Erlander, Chief Executive Officer of Cardiff Oncology, stated that the data supports their belief that onvansertib has the potential to change the treatment paradigm for first-line RAS-mutated mCRC patients.

Industry Context

This announcement is significant as it presents a potential new treatment option for first-line RAS-mutated mCRC, a patient population with limited treatment advancements in the past two decades. The positive results could position Cardiff Oncology as a key player in the oncology space.

Comparison to Industry Standards

• Historical control data for first-line mCRC treatment shows an objective response rate of 38% (Hecht et al., J Clin Oncol 2009).
• The 64% ORR observed in the 30mg onvansertib arm is significantly higher than this historical benchmark.
• The study is comparing onvansertib in combination with standard of care (FOLFIRI/bev or FOLFOX/bev) against standard of care alone.
• The results suggest that onvansertib may offer a superior treatment option compared to current standard of care for this patient population.
• Other companies developing treatments for mCRC include companies such as Amgen, Bayer, and Eli Lilly, but this trial is specifically targeting the RAS-mutated population.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with RAS-mutated mCRC may benefit from a new treatment option.
• Employees of Cardiff Oncology may be motivated by the positive trial results.
• The company's partners and collaborators may see increased value in their relationships.

Next Steps

• The company will continue to enroll patients in the CRDF-004 trial.
• Additional clinical data from the CRDF-004 trial is expected in the first half of 2025.
• The company will hold a conference call to discuss the results.

Key Dates

Keywords

onvansertib, mCRC, colorectal cancer, RAS-mutated, PLK1 inhibitor, clinical trial, objective response rate, FOLFIRI, FOLFOX, bevacizumab, cancer therapy